Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INMB INmune Bio	$2.09 -9.5%	$7.21	$1.89 ▼ $11.64	$53.09M	1.34	734,105 shs	8.75 million shs
NVCT Nuvectis Pharma	$7.31 -2.1%	$9.09	$4.44 ▼ $11.80	$156.07M	-0.25	133,436 shs	122,273 shs
PBYI Puma Biotechnology	$3.59 +4.7%	$3.29	$2.23 ▼ $4.13	$170.23M	1.29	414,871 shs	586,008 shs
RVPH Reviva Pharmaceuticals	$0.37 -3.1%	$0.81	$0.30 ▼ $4.28	$18.29M	-0.06	1.32 million shs	2.05 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INMB INmune Bio	-9.52%	-68.38%	-71.98%	-74.10%	-75.18%
NVCT Nuvectis Pharma	-2.14%	-8.40%	-20.28%	-22.73%	+18.28%
PBYI Puma Biotechnology	+4.66%	+6.85%	+7.81%	+19.27%	+9.45%
RVPH Reviva Pharmaceuticals	-3.07%	-54.11%	-61.92%	-34.24%	-68.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INMB INmune Bio	1.6527 of 5 stars	3.4	0.0	2.1	1.7	0.6
NVCT Nuvectis Pharma	3.1279 of 5 stars	3.5	0.0	3.3	5.0	0.6
PBYI Puma Biotechnology	4.2809 of 5 stars	3.5	2.0	2.6	4.2	3.1
RVPH Reviva Pharmaceuticals	2.5874 of 5 stars	3.6	1.0	1.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INMB INmune Bio	2.71	Moderate Buy	$22.80	990.91% Upside
NVCT Nuvectis Pharma	3.00	Buy	$17.00	132.56% Upside
PBYI Puma Biotechnology	3.00	Buy	$7.00	94.99% Upside
RVPH Reviva Pharmaceuticals	3.29	Buy	$9.00	2,336.38% Upside

Current Analyst Ratings Breakdown

Latest RVPH, NVCT, INMB, and PBYI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/27/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/3/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/20/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $3.00
4/30/2025	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $15.00
4/24/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/2/2025	NVCT Nuvectis Pharma	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INMB INmune Bio	$10K	4,802.82	N/A	N/A	$1.45 per share	1.44
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.50 per share	N/A
PBYI Puma Biotechnology	$230.50M	0.77	$0.89 per share	4.03	$1.88 per share	1.91
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)
NVCT Nuvectis Pharma	-$19M	-$1.13	N/A	N/A	N/A	N/A	-148.83%	-95.60%	8/5/2025 (Estimated)
PBYI Puma Biotechnology	$30.28M	$0.77	4.66	9.45	N/A	16.37%	49.35%	18.25%	7/30/2025 (Estimated)
RVPH Reviva Pharmaceuticals	-$29.92M	-$0.79	N/A	N/A	N/A	N/A	N/A	-302.31%	8/13/2025 (Estimated)

Latest RVPH, NVCT, INMB, and PBYI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	RVPH Reviva Pharmaceuticals	-$0.21	-$0.13	+$0.08	-$0.13	N/A	N/A
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/6/2025	Q1 2025	NVCT Nuvectis Pharma	-$0.30	-$0.27	+$0.03	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INMB INmune Bio	N/A	2.64	2.64
NVCT Nuvectis Pharma	N/A	3.28	3.28
PBYI Puma Biotechnology	0.11	1.53	1.43
RVPH Reviva Pharmaceuticals	N/A	0.54	0.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INMB INmune Bio	12.72%
NVCT Nuvectis Pharma	96.77%
PBYI Puma Biotechnology	61.29%
RVPH Reviva Pharmaceuticals	63.18%

Insider Ownership

Company	Insider Ownership
INMB INmune Bio	35.70%
NVCT Nuvectis Pharma	30.52%
PBYI Puma Biotechnology	23.30%
RVPH Reviva Pharmaceuticals	27.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INMB INmune Bio	10	22.98 million	14.78 million	Optionable
NVCT Nuvectis Pharma	8	20.89 million	14.52 million	Not Optionable
PBYI Puma Biotechnology	200	49.63 million	38.07 million	Optionable
RVPH Reviva Pharmaceuticals	5	48.00 million	34.96 million	Optionable

RVPH, NVCT, INMB, and PBYI Headlines

Recent News About These Companies

Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.com

June 29 at 8:33 AM | investing.com

Reviva Dives on Stock Offering

June 26, 2025 | baystreet.ca

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

June 26, 2025 | globenewswire.com

Reviva Pharmaceuticals stock falls after announcing public offering

June 25, 2025 | za.investing.com

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

June 25, 2025 | globenewswire.com

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

June 5, 2025 | finance.yahoo.com

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 5, 2025 | globenewswire.com

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

June 2, 2025 | globenewswire.com

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025 | santelog.comS

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025 | globenewswire.com

Reviva to Participate in the A.G.P. Healthcare Company Showcase

May 13, 2025 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)

May 4, 2025 | theglobeandmail.com

Reviva to Participate in the Citizens Life Sciences Conference

April 29, 2025 | finance.yahoo.com

RVPH: M&A Deals Highlight Brilaroxazine Value

April 7, 2025 | finance.yahoo.com

Roth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)

April 5, 2025 | markets.businessinsider.com

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

March 31, 2025 | markets.businessinsider.com

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

March 30, 2025 | globenewswire.com

Why Reviva Pharmaceuticals Holdings, Inc.’s (RVPH) Stock Is Down 10.61%

March 7, 2025 | aaii.comA

Unusually active option classes on open February 12th

February 12, 2025 | markets.businessinsider.com

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 4, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH, NVCT, INMB, and PBYI Company Descriptions

INmune Bio NASDAQ:INMB

$2.09 -0.22 (-9.52%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$2.08 -0.01 (-0.48%)

As of 06:33 AM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Nuvectis Pharma NASDAQ:NVCT

$7.31 -0.16 (-2.14%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$7.32 +0.01 (+0.14%)

As of 07/1/2025 05:26 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Puma Biotechnology NASDAQ:PBYI

$3.59 +0.16 (+4.66%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$3.66 +0.06 (+1.81%)

As of 04:35 AM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.37 -0.01 (-3.07%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$0.37 +0.00 (+1.25%)

As of 06:03 AM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time